A Personalized Prevention Program (PPP) Based on the Comprehensive Geriatric Assessment (CGA) for the Prevention of Multidimensional Frailty Related to Non-communicable Chronic Diseases (NCDs) in Older People
NCT ID: NCT06224556
Last Updated: 2024-08-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
1216 participants
INTERVENTIONAL
2024-06-04
2025-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* The Comprehensive Geriatric Assessment (CGA) is the gold standard in the geriatric clinical context
* Recently, in Italy the first Guidelines about the CGA in different settings for older people has been pubblicated
* The CGA can identify older people at high risk of frailty who can benefit from a personalized prevention program
* No studies has been investigated the effects of a personalized prevention program (PPP) based on the CGA in a primary care setting
* The main hypothesis is that the CGA assessment can result in personalized prevention programs for older subjects in primary care settings with an effect in reducing the hospitalization rate and can be related to the biological paramters in NCDs
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Validation of a Record-based Frailty Assessment According to the Multidimensional Prognostic Index
NCT03794674
Evaluating the Efficacy of a Detection and Prevention Program for Frail Community-dwelling Older Adults
NCT03168204
Integration of Clinical, Biological and Psycho-social Variables for a Gender-sensitive Frailty Prediction
NCT07109596
Comprehensive Geriatric Assessment in the Elderly Subjects (PROMISING)
NCT05822154
Clinical and Economic Assessment of a Pre-frail Screening Program
NCT02138968
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study involves 1216 subjects enrolled by General Practitioners (GPs) in four different Italian Areas.
The GPs involved will be randomised to clusters in a 1:1 ratio, therefore one group of GPs will enrol patients for the Intervention Group and a second group of GPs will include patients for the Control Group.
The sample size:
A recent Cochrane systematic review reports a significant reduction in the risk of unplanned hospitalisation in community-dwelling elderly persons treated with VMD compared to standard clinical practice (RR= 0.83; CI 95%: 0.70-0.99). Thus, assuming an incidence of unplanned hospitalisations in one year of 38.8% in the group receiving PPP compared to 47.7% in the group randomised to standard care and assuming a power of 80% and a type I error of 5%, a total of 972 participants will be enrolled. Furthermore, assuming a drop-out rate of 20% over the 1-year follow-up period, the final sample will be 1216 participants, 608 in each group
608 subjects will be involved in the intervention group: they will receive the Personalized Prevention Program (PPP) and a saliva sample will be collected.
608 subjects will be involved in the control group according to the normal clinical practice.
Both groups will be contacted at 6 and 12 months after the baseline for the follow-up.
Statistical analyses:
Baseline characteristics will be compared between the group receiving the CGA-based PPP intervention and the control group. Continuous variables will be compared using the t-Student test and categorical variables using the Chi-square test. The cumulative probability of the primary and secondary outcome will be estimated by Kaplan-Meier curve, using the log-rank test to assess differences between the two groups. To assess the risk associated with the primary outcome (rate of unplanned hospitalisation at 12 months) in subjects in the intervention group compared to subjects in standard care, the Hazard Ratio (HR) will be estimated by fitting a Cox model, after testing for proportional hazards. Similarly, the risk of secondary outcomes will be estimated.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
be evaluated by a Comprehensive Geriatric Assessment thanks to the Multidimensional Prognostic Index (MPI) questionnaire.
PREVENTION
SINGLE
Therefore, the role of GPs are masked.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention Group
All the 608 patients will be evaluated by their General Practitioners through the Brief-MPI scale, which is based on the Comprehensive Geriatric Assessment (CGA).
Based on the score obtained at the Brief-MPI, the patient will receive a Personalised Prevention Program (PPP) concerning the following domains: 1) motor, 2) cognitive, 3) nutritional, 4) polypharmacotherapy, 5) vaccination prevention, 6) basal and instrumental activities, 7) co-habitation. Patients will receive brochures containing practical advice and recommendations to be implemented over a 12-month period; in the case of high Brief-MPI risk scores, patients will be referred for specialist examinations and/or in-depth diagnostics.
In addition, saliva samples will be collected to assess biomarkers of oxidative stress and, in a subsample of 210 subjects, the composition of the oral microbiota will also be analysed.
Brief-MPI assessment (based on the Comprehensive Geriatric Assessment); Personalized Prevention Program
Patients will be evaluated at baseline and at 6 and 12 months after the baseline through the CGA, the Resilience Scale (RS-14 items) and the Psychological General Wellbeing Index short form.
The prevention program will be received at the baseline, so at the two follow-ups patients wiil asked the adherence to it and the level of satisfaction (Client Satisfaction Questionnaire - 8 items).
Saliva sample will be collected and analyzed.
Control group
Patients will receive the standard clinical practice by their General Practitioners, without being evaluated by the CGA or receiving the personalized prevention program (PPP). No saliva sample will be collected.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Brief-MPI assessment (based on the Comprehensive Geriatric Assessment); Personalized Prevention Program
Patients will be evaluated at baseline and at 6 and 12 months after the baseline through the CGA, the Resilience Scale (RS-14 items) and the Psychological General Wellbeing Index short form.
The prevention program will be received at the baseline, so at the two follow-ups patients wiil asked the adherence to it and the level of satisfaction (Client Satisfaction Questionnaire - 8 items).
Saliva sample will be collected and analyzed.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 1 non-communicable chronic disease
* Signed informed consent
Exclusion Criteria
* \<65 years old
* without non-communicable chronic diseases
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alberto Pilotto
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alberto Pilotto
Director of Department of Geriatric Care, Orthogeriatrics and Rehabilitation
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alberto Pilotto
Role: PRINCIPAL_INVESTIGATOR
Director of the Department of Geriatric Care, orthogeroatric and rehabilitation, EO Galliera Hospital, Genova, Italy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Polimedica Societa' Cooperativa
Bari, , Italy
Medici Insieme Garda Valsabbia Societa' Cooperativa
Desenzano del Garda, , Italy
Ambulatori medici
Florence, , Italy
COMEGEN Società Cooperativa Sociale
Napoli, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Pilotto A, Morganti W, Seminerio E, Lacorte E, Custodero C, Veronese N, Fielding P, Massone C, Piscopo P, Fabrizi E, Lorenzini P, Magni A, Piccinocchi G, Ignazzi C, Busco L, Barbagallo M, Massone C, Aprile PL, Vanacore N. Usefulness of the BRIEF-Multidimensional Prognostic Index (BRIEF-MPI) to identify older adults' healthcare needs to be addressed with a Personalized Prevention Program in general practice: preliminary data from the PrimaCare_P3 study. BMC Prim Care. 2025 Oct 27;26(1):323. doi: 10.1186/s12875-025-02951-6.
Pilotto A, Barbagelata M, Lacorte E, Custodero C, Veronese N, Maione V, Morganti W, Seminerio E, Piscopo P, Fabrizi E, Lorenzini P, Carbone E, Lora Aprile P, Solfrizzi V, Barbagallo M, Vanacore N; PrimaCare_P3 study group. A multicomponent personalized prevention program in the primary care setting: a randomized clinical trial in older people with noncommunicable chronic diseases (Primacare_P3 study). Trials. 2024 Sep 13;25(1):611. doi: 10.1186/s13063-024-08413-1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PNRR-MAD-2022-12376781
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.